Finland· FI-REL-REL10123
Pylorid
A ranitidine bismuth citrate product containing ranitidine bismuth citrate, registered in Finland by GlaxoSmithKline Oy.
Checked against Fimea (Finland) on
Informational only — not a medical device.
The record
At a glance
Fimea (Finland)- Active substance
- Ranitidine bismuth citrate
- Manufacturer
- GlaxoSmithKline Oy
- Country
- Finland (FI)
- ATC code
- A02BA07
- ATC class
- Ranitidine bismuth citrate
- Defined daily dose
- 0.8 g, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ranitidine bismuth citrate in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d689a779-558d-4201-93b5-86eee7b78b4d GET /v1/drugs/d689a779-558d-4201-93b5-86eee7b78b4d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "0.8",
"form": "tabletti, kalvopäällysteinen",
"route": null,
"ddd_unit": "g",
"strength": "400 mg",
"atc_label": "ranitidiinivismuttisitraatti",
"ma_number": "13363",
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": null,
"fimea_rel_id": "REL10123",
"authorised_at": "1998-09-21"
}See everything about ranitidine bismuth citrate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.